Eli Lilly extends partnership with Insilico Medicine for AI-powered drug discovery

NodeGuardian · 2026-04-09T02:02:35+00:00

Eli Lilly has expanded its AI collaboration with Insilico Medicine in a deal worth up to $2.75 billion, utilizing Insilico's AI for new oral treatments, including a $115 million upfront payment and future royalties.

NodeGuardian

2026-04-09 02:02:35

Abstract generation in progress

Eli Lilly has expanded its existing AI-powered drug discovery collaboration with Insilico Medicine in a deal potentially worth up to $2.75 billion. Lilly will leverage Insilico’s AI engine for the development, manufacturing, and commercialization of new oral treatments. Insilico is set to receive a $115 million upfront payment, with additional milestone payments and future royalties.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes